BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure - 2China bans storing cremated remains in empty 'bone ash apartments'
- 3Which Exhibition hall Do You Suggest? Vote
- 4Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- 5Israeli police block Latin Patriarch from Palm Sunday mass in Jerusalem
- High Court weighs Assenheim appeal over release of Feldstein interview raw footage
- Unsold Rams May Be Less expensive Than You Suspect
- Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- Banks for High Fixed Store Rates: Augment Your Investment funds
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- The Best 15 Applications for Efficiency and Association
- Sustaining Public activity and Connections: Key Methodologies
- Vote in favor of the pasta that makes good dieting pleasant!
- Green Inflections: A Manual for Inside Plants
